Nikita Smirnov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Nikita Smirnov has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- I. V. Predeina
Privolzhsky Research Medical University
2 shared publications - Irina Vasilievna Mukhina
Privolzhsky Research Medical University
2 shared publications - M. Yu. Skorkina
Institute of Fundamental Medicine, Privolzhsky Research Medical University, 10/1 Minin Sq., Nizhniy Novgorod 603005, Russia
2 shared publications - Tatiana Kovaleva
Institute of Fundamental Medicine, Privolzhsky Research Medical University, 10/1 Minin Sq., Nizhniy Novgorod, 603005, Russia, Russia
1 shared publication - Tatiana Kovaleva
Institute of Fundamental Medicine, Privolzhsky Research Medical University, 10/1 Minin Sq., Nizhniy Novgorod 603005, Russia
1 shared publication
Latest Publications
- Open Access
Pax6 as a Therapeutic Target: Convergent Molecular Pathways in the Regulation of Aniridia, Neurogenesis, Neurodegeneration and Oncology
Pax6 is a multifunctional transcription factor that orchestrates cell cycle progression at distinct stages of early embryonic neurogenesis and serves as a molecular mediator integrating multiple signaling pathways associated with pathological processes. Within this framework, Pax6 is regarded as an attractive molecular target for developing new drugs aimed at combating neurodegeneration, oncology, and aniridia. The present review aims to examine published studies describing various Pax6-dependent molecular pathways to identify common principles and condition-specific differences in Pax6-regulated cascades in health and disease. These insights may contribute to the conceptual foundation for developing new therapeutic strategies targeting Pax6 as a molecular regulator. This review summarizes the data demonstrating a central role of Pax6 in governing the neuronal cell cycle in health and pathology. It is possible that Pax6 may act as a therapeutic target in certain pathophysiological conditions; however, the effectiveness of such a strategy will depend on the substrate chain in the signaling pathway, its branching, and the redundancy of mediators involved.
Open AccessPax6 as a Therapeutic Target: Convergent Molecular Pathways in the Regulation of Aniridia, Neurogenesis, Neurodegeneration and Oncology
Pax6 is a multifunctional transcription factor that orchestrates cell cycle progression at distinct stages of early embryonic neurogenesis and serves as a molecular mediator integrating multiple signaling pathways associated with pathological processes. Within this framework, Pax6 is regarded as an attractive molecular target for developing new drugs aimed at combating neurodegeneration, oncology, and aniridia. The present review aims to examine published studies describing various Pax6-dependent molecular pathways to identify common principles and condition-specific differences in Pax6-regulated cascades in health and disease. These insights may contribute to the conceptual foundation for developing new therapeutic strategies targeting Pax6 as a molecular regulator. This review summarizes the data demonstrating a central role of Pax6 in governing the neuronal cell cycle in health and pathology. It is possible that Pax6 may act as a therapeutic target in certain pathophysiological conditions; however, the effectiveness of such a strategy will depend on the substrate chain in the signaling pathway, its branching, and the redundancy of mediators involved.
- Open Access
- 29 October 2025
- Published by MDPI AG in Preprints.org
Pax6 as a Therapeutic Target: Convergent Molecular Pathways in the Regulation of Aniridia, Neurogenesis, Neurodegeneration and Oncology
The transcription factor Pax6 acts as a molecular switch regulating various phases of the cell cycle during the early stages of embryonic neurogenesis and serves as a molecular mediator integrating multiple signaling pathways involved in the development of pathophysiological conditions. In this regard, Pax6 is considered an attractive molecular target for developing new drugs aimed at combating neurodegeneration, oncology, and aniridia. The aim of this review is to examine the range of studies describing various Pax6-dependent molecular pathways to identify similarities and differences in the signaling cascades activated by Pax6 in health and disease. These insights may provide a basis for developing new therapeutic strategies targeting Pax6 as a molecular regulator. This review summarizes the data indicating the leading regulatory role of Pax6 in the neuronal cell cycle in health and pathology. It is possible that Pax6 may act as a therapeutic target in certain pathophysiological conditions; however, the effectiveness of such a strategy will depend on the substrate chain in the signaling pathway, its branching, and the redundancy of mediators involved.
- 29 October 2025
- Published by MDPI AG in Preprints.org
Open AccessPax6 as a Therapeutic Target: Convergent Molecular Pathways in the Regulation of Aniridia, Neurogenesis, Neurodegeneration and Oncology
The transcription factor Pax6 acts as a molecular switch regulating various phases of the cell cycle during the early stages of embryonic neurogenesis and serves as a molecular mediator integrating multiple signaling pathways involved in the development of pathophysiological conditions. In this regard, Pax6 is considered an attractive molecular target for developing new drugs aimed at combating neurodegeneration, oncology, and aniridia. The aim of this review is to examine the range of studies describing various Pax6-dependent molecular pathways to identify similarities and differences in the signaling cascades activated by Pax6 in health and disease. These insights may provide a basis for developing new therapeutic strategies targeting Pax6 as a molecular regulator. This review summarizes the data indicating the leading regulatory role of Pax6 in the neuronal cell cycle in health and pathology. It is possible that Pax6 may act as a therapeutic target in certain pathophysiological conditions; however, the effectiveness of such a strategy will depend on the substrate chain in the signaling pathway, its branching, and the redundancy of mediators involved.